Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. - Wikidata - awgldk - TriplyDB

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

http://www.wikidata.org/entity/Q34021957

about

Targeted therapy for advanced renal cell carcinoma Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Sequence of treatment in locally advanced and metastatic renal cell carcinoma Cytoreductive surgery in the era of targeted molecular therapy Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review Population pharmacokinetics of bevacizumab in cancer patients with external validation Cytoreductive nephrectomy and its role in the present-day period of targeted therapy.Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12 Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities Lessons learned from the bevacizumab experience Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma Targeted therapeutic strategies for the management of renal cell carcinoma Circulating biomarkers in advanced renal cell carcinoma: clinical applications Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1 Sunitinib in the treatment of metastatic renal cell carcinoma Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?Molecular mechanisms and clinical applications of angiogenesis Immunotherapy for metastatic renal cell carcinoma.Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers Ethical Issues in the Management of Renal Cell Carcinoma.Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer.Immunotherapy in genitourinary malignancies.The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future.Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review Adaptive immunity in cancer immunology and therapeutics.

P2860

Q24242946-85D36458-E164-4480-ABAF-495379BA3FBA Q26766240-40276FB5-8357-4AB9-BAE8-491DE63D0096 Q26768267-346BBDD9-C893-4FFA-9CDD-CBDA88866BB5 Q26769884-0B58E996-6E55-41BA-8756-B7107691D2DB Q26773653-6104F647-BF2D-4B5F-A8CB-F425A4B2FC6E Q26774134-43E5904E-8990-4CAC-A36F-429D9149D331 Q26774515-497E47EF-54A6-4908-87F2-AB26A10E718E Q26779580-F69E2BFD-0256-4369-90A9-2B98AEA9CD7A Q26783520-C9BFF398-F788-4C2D-8CA7-BC693F871737 Q26796316-04307227-6C53-4763-B8CA-2301F6471031 Q26801279-B98B3EBF-47DF-4D0D-9B0E-2160DE9ADF87 Q26824086-64CDB7E3-7C79-4ACC-8CED-78C189718A94 Q26827319-5BBF1947-19D6-4DD8-86CC-0F210AAD920B Q26852437-73D11EF5-8DFA-4662-A443-52335058F6EC Q26852509-2C1334E4-A329-47FD-8E39-0B2A9DF88B9D Q26852704-D4CC96BD-8540-4000-9AB1-73E632071B33 Q26991589-31B62786-3767-410D-BCC1-D8B1DB04D19C Q27013665-2F3DEC64-C769-4A44-8CEF-3EEEF4F809F8 Q27013846-DAC7098C-8A8E-4FCD-91B6-0C1A92D835C6 Q27023770-C4B6DDFE-8726-4BB1-B97F-9847EFBA20B5 Q27026961-7798F83C-139F-4BF4-A1AE-522AF98C7C60 Q27028048-A733FF6D-5671-4FA0-AD8F-52ACF379BC8B Q28066747-5404CF17-0574-4837-A1AC-1ED506DB338E Q28069924-768ADA33-5388-466A-82E6-74D97D3982D3 Q28072057-59A17B5F-6E03-414E-85E6-4F87083CCDF5 Q28301672-7A7F34BD-9BF7-4F91-B469-FA4B1A80D2AB Q29547314-9DF63775-4CE5-4327-AA16-BCEA7E7DCE3F Q30234458-B988439A-A698-4B8B-ADF0-C167825CD8DB Q30399006-84A6A133-5E8B-4478-8529-AEE4888A38A8 Q30472042-9D68EA90-C383-4A3C-8E2B-93E2168F9F24 Q30724257-85105F68-7F67-4EE5-A9E9-39E7F7FA44F5 Q31060162-E43E7C9E-27C0-499C-A0C9-0FD4B9CFD575 Q33395466-3C17BC25-04BD-45FB-87FD-4B1938BEDDB7 Q33408836-60BC28F8-C437-4C62-9752-528C52DB2C6C Q33593800-8F5FBDA9-FB07-4021-BB06-17C32D1745E3 Q33705268-5934B39D-A0D3-4A73-B238-2E0B19A5B7FF Q33712944-544C4CBC-C2D6-4498-B422-849D22C9E89B Q33740717-511D7355-D122-4B91-A095-0B32AA7FAD3B Q33761655-05591CE9-71C0-4FEE-B1AE-3BEC0F181D46 Q33893934-2EE04102-96D8-42B7-A0EC-A8C3D9B96786

P2860

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

http://www.wikidata.org/entity/Q34021957

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase III trial of bevacizumab ...... analysis of overall survival.

@ast

Phase III trial of bevacizumab ...... analysis of overall survival.

@en

Phase III trial of bevacizumab ...... etastatic renal cell carcinoma

@nl

type

label

Phase III trial of bevacizumab ...... analysis of overall survival.

@ast

Phase III trial of bevacizumab ...... analysis of overall survival.

@en

Phase III trial of bevacizumab ...... etastatic renal cell carcinoma

@nl

prefLabel

Phase III trial of bevacizumab ...... analysis of overall survival.

@ast

Phase III trial of bevacizumab ...... analysis of overall survival.

@en

Phase III trial of bevacizumab ...... etastatic renal cell carcinoma

@nl

P1433

Q34021957-8726D8E6-73EE-4281-9888-0DDB7AFE44C3

P1476

Q34021957-2C3C5B0C-770E-440A-8608-FC85CA5309C7

P2093

Q34021957-0B9251B4-87E8-4F44-A2FD-080C3C5E36B1

Q34021957-4107949B-30A9-404C-91D3-BC4C4F25C0C0

Q34021957-6EBD2F9C-290E-4AC5-9170-7D5FD2B521DA

Q34021957-81F9FE3A-4C1E-410F-81A3-482C54E0917A

Q34021957-B826C43E-F55C-4EB9-AA00-EAD8F3AFCF6D

Q34021957-C90039A7-E5A8-428E-97DC-7FAC1A762CD5

Q34021957-E796111F-4B24-4A41-91F3-3A833413668E

Q34021957-F5CB911A-E274-42AD-B330-DAF6E65A0A6A

Q34021957-FC067552-6A82-4F87-8890-FE5FAD2A15F6

P304

Q34021957-FE161EE1-776C-42D5-9FC4-789BC6D61A8E

P31

Q34021957-9A016F1A-94E8-4E83-955A-E779F0FC8275

P356

Q34021957-2435BB7B-4775-427B-B64B-FBB5FB213A27

P407

Q34021957-56F3B28B-6BA8-4452-9F5F-A4D16D4A2A1C

P433

Q34021957-378ADEB6-7618-4211-BA12-B83504E1CD94

P478

Q34021957-71280D5C-C59E-4687-A7AF-28D961F30810

P50

Q34021957-83FC581E-4E47-4BB0-B23F-6369BAC2B332

P577

Q34021957-E9B23EEC-5836-4DEC-A68B-F1F4B1FEEE8F

P698

Q34021957-57A4A8BF-1FE8-4D43-A42C-82F217F0ABDA

P921

Q34021957-00653615-A53A-4FEA-BD3C-80BDD544FE23

Q34021957-5797293D-76A2-4058-B9B8-8A49F374D6A3

Q34021957-8BA9CBFB-C8D4-4851-A78F-04F0FF3F41DE

P356

JCO.2009.26.7849

P1433

Journal of Clinical Oncology

P1476

Phase III trial of bevacizumab ...... analysis of overall survival.

@en

P2093

Alain Ravaud

http://www.w3.org/2001/XMLSchema#string

Bohuslav Melichar

http://www.w3.org/2001/XMLSchema#string

Emilio Bajetta

http://www.w3.org/2001/XMLSchema#string

Joaquim Bellmunt

http://www.w3.org/2001/XMLSchema#string

Sangeeta Jethwa

http://www.w3.org/2001/XMLSchema#string

Sergio Bracarda

http://www.w3.org/2001/XMLSchema#string

Sophie Golding

http://www.w3.org/2001/XMLSchema#string

Sylvie Négrier

http://www.w3.org/2001/XMLSchema#string

Vesna Sneller

http://www.w3.org/2001/XMLSchema#string

P304

2144-2150

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.26.7849

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Bernard Escudier

P577

2010-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20368553

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial